HeXie Biomedical

Hexie Biomedical is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the development of innovative gene therapies for rare and life-threatening diseases. The company utilizes a proprietary adeno-associated virus (AAV) vector platform to design high-efficiency capsids with improved tissue targeting and reduced immunogenicity. Its lead candidate, HX-001, is an AAV-based gene therapy for Hemophilia B that has received IND approval and entered clinical development. Hexie's broader pipeline includes programs for Duchenne muscular dystrophy (DMD) and various ophthalmic conditions, aiming to address significant unmet medical needs. The company is backed by prominent venture capital firms, including Legend Capital and Northern Light Venture Capital, and operates out of the Suzhou Industrial Park (BioBAY). By leveraging advanced R&D and manufacturing capabilities, Hexie Biomedical seeks to provide long-term therapeutic benefits with improved safety profiles compared to existing treatments.